Login to Your Account



Search

Search results

Pharma: Clinic roundup

Pfizer Inc. , of New York, reported top-line results from a Phase III study of ALO-02 (oxycodone hydrochloride/naltrexone hydrochloride extended-release capsules) in patients with moderate to severe chronic low back pain, showing that the drug met th ...

BioWorld Today - Staff - 2014-01-24 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Takeda Pharmaceutical Co. Ltd. , of Osaka, Japan, said Takeda Development Center Shanghai and Takeda Development Center Asia Pte. Ltd., started the Phase III TOURMALINE-MM1 global study with the oral proteasome inhibitor, ixazomib, in relapsed and/or ...

BioWorld Today - Staff - 2014-01-23 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, said a new smoking-cessation clinical study assessing the efficacy and safety of Chantix/Champix (varenicline) met its primary and secondary endpoints. (BioWorld-Today-2014-01-22) ...

BioWorld Today - Staff - 2014-01-22 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Ipsen SA , of Paris, said the results of the ELECT Phase III trial testing Somatuline Autogel/Somatuline Depot (lanreotide) showed a statistically significant reduction vs. placebo in the number of days in which immediate-release octreotide was used ...

BioWorld Today - Staff - 2014-01-21 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Takeda Pharmaceutical Co. Ltd. , of Osaka, Japan, said vedolizumab, a humanized monoclonal antibody antagonizing alpha4beta7 intregrin for treating moderate and severe ulcerative colitis and Crohn’s disease, entered two new Phase III trials in Japan. ...

BioWorld Today - Staff - 2014-01-09 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Lurasidone, an atypical antipsychotic developed by Dainippon Sumitomo Pharma Co. Ltd. , of Osaka, Japan, and marketed by its subsidiary Sunovion Pharmaceuticals Inc., of Marlborough, Mass., was the subject of five poster presentations at ...

BioWorld Today - Staff - 2013-10-14 23:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

Merck & Co. Inc., of Whitehouse Station, N.J., is collaborating with Glaxosmithkline plc, of London, to test Merck’s anti-PD-1 immunotherapy, MK-3475, with GSK’s oral kinase inhibitor, pazopanib, in advanced renal cell carcinoma. The compani ...

BioWorld Today - Staff - 2013-12-19 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Ipsen SA , of Paris, reported initial results from the 243-patient Phase III study of Dysport (abobotulinumtoxinA) in adult upper limb spasticity, showing statistically significant response vs. placebo in the improvement of muscle tone, as measured ...

BioWorld Today - Staff - 2013-12-18 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Boehringer Ingelheim GmbH , of Ingelheim, Germany, reported new data from its Phase III trial, Startverso, which evaluated faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV) in patients with genotype-1 hepatitis C (HCV) ...

BioWorld Today - Staff - 2013-12-17 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, reported results showing that pantoprazole magnesium 40 mg, branded Tecta, was as effective as esomeprazole 40 mg for achieving complete remission in patients with erosive gastroesophageal reflux disease, ...

BioWorld Today - Staff - 2013-12-16 00:00 - 0 comments - 0 attachments